Loading clinical trials...
Loading clinical trials...
A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD
Conditions
Interventions
Visudyne
Kenalog
Locations
2
United States
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States
Vh/UBC Eye Care Centre
Vancouver, British Columbia, Canada
Start Date
October 1, 2003
Completion Date
January 1, 2007
Last Updated
July 12, 2007
NCT05913063
NCT06990269
NCT06970665
NCT07160179
NCT06557460
NCT05562947
Lead Sponsor
Manhattan Eye, Ear & Throat Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions